Methods	PARALLEL RANDOMIZED CONTROLLED CLINICAL TRIAL
Participants	INCLUSION CRITERIA: Newly diagnosed Type 2 diabetes mellitus
	EXCLUSION CRITERIA: Not reported
	DIAGNOSTIC CRITERIA: Not reported
	CO-MORBIDITIES: Not reported
	CO-MEDICATIONS: Apparently none
Interventions	NUMBER OF STUDY CENTRES: Single
	COUNTRY/ LOCATION: India
	SETTING: Outpatients attending a Medical College Hospital
	INTERVENTION(ROUTE,TOTALDOSE/DAY, FREQUENCY):Treatment group received Inolter (each capsule of Inolter contains Mormordica charantia 1OO mg, Trigonella Faenum Graecum 100 mg, Asphalt 100 mg, Gymnema Sylvestre 100 mg, Eugenia Jambolina 100 mg). Dose and frequency of administration not mentioned
	CONTROL (ROUTE, TOTAL DOSE/DAY, FREQUENCY): Controls received identical looking placebo - dose and frequency of administration not mentioned. Diet and exercise were continued for both groups
	TREATMENT BEFORE STUDY: None for diabetes
	TITRATION PERIOD: Not reported
Outcomes	PRIMARY OUTCOME(S) (as stated in the publication): Glycaemic control (FBS, HbA1c) and changes in lipid profile
	SECONDARY OUTCOMES (as stated in the publication): None mentioned
	ADDITIONAL OUTCOMES: None reported
Notes	No withdrawals reported

Risk of bias
Bias	Authors’ judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	not described
Allocation concealment (selection bias)	Unclear risk	not described
Blinding (performance bias and detection bias) All outcomes	Low risk	coded and identical looking active medication or placebo
Incomplete outcome data (attrition bias) All outcomes	Low risk	no withdrawals reported
Selective reporting (reporting bias)	Unclear risk	no protocol available
Other bias	Low risk	nothing detected